Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha1-proteinase inhibitor subcutaneous (human) 15%
- Development stage
- Phase 3
- Lead developer
- Grifols
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% is a plasma-derived biologic therapy developed by Grifols Therapeutics LLC for the treatment of alpha1-antitrypsin deficiency (AATD). It is a high-concentration (15%) formulation of alpha1-proteinase inhibitor (AAT), a protective protein that inhibits neutrophil elastase and other proteases to prevent lung tissue destruction. Unlike standard intravenous augmentation therapies that require frequent hospital visits, this formulation is designed for subcutaneous administration, potentially allowing for self-administration at home. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and pharmacokinetics in patients with AATD and emphysema.
- Other names
- Alpha1-Proteinase Inhibitor Subcutaneous 15%Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous
02
Targets
ELANE (Human Neutrophil Elastase)PLG (Plasminogen)F2 (Thrombin)
Beyond the preview
Go deeper on alpha1-proteinase inhibitor subcutaneous (human) 15%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha1-proteinase inhibitor subcutaneous (human) 15%.